Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Fish and Richardson
UBS
Farmers Insurance
Cantor Fitzgerald
Federal Trade Commission
AstraZeneca
Covington
Dow

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020655

« Back to Dashboard

NDA 020655 describes ALORA, which is a drug marketed by Allergan Sales Llc and is included in one NDA. It is available from two suppliers. Additional details are available on the ALORA profile page.

The generic ingredient in ALORA is estradiol. There are seventy-five drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the estradiol profile page.
Summary for 020655
Tradename:ALORA
Applicant:Allergan Sales Llc
Ingredient:estradiol
Patents:0
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers)
Formulation / Manufacturing:see details
Pharmacology for NDA: 020655
Ingredient-typeEstradiol Congeners
Mechanism of ActionEstrogen Receptor Agonists
Medical Subject Heading (MeSH) Categories for 020655
Suppliers and Packaging for NDA: 020655
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655 NDA Allergan, Inc. 0023-5885 N 0023-5885-12
ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655 NDA Allergan, Inc. 0023-5886 N 0023-5886-15

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength0.05MG/24HR
Approval Date:Dec 20, 1996TE:BXRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength0.075MG/24HR
Approval Date:Dec 20, 1996TE:BXRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength0.1MG/24HR
Approval Date:Dec 20, 1996TE:BXRLD:No

Expired US Patents for NDA 020655

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655-001 Dec 20, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Sales Llc ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655-004 Apr 5, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Sales Llc ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655-004 Apr 5, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Sales Llc ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655-003 Dec 20, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Chubb
Farmers Insurance
Baxter
Julphar
Teva
US Army
Daiichi Sankyo
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.